Posted by Michael Wonder on 26 Oct 2016
Portola Pharmaceuticals submits new drug application to U.S. FDA for betrixaban for extended duration prophylaxis of venous thromboembolism in acute medically ill patients
25 October 2016 - Betrixaban, an FDA fast track-designated therapy, would be first anti-coagulant for hospital to home prevention of venous thromboembolism in this high-risk patient population.
Portola Pharmaceuticals Inc. today announced that it has submitted a new drug application to the U.S. FDA seeking approval to market betrixaban for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE.
Betrixaban, an FDA fast track-designated investigational drug, is an oral, once-daily Factor Xa inhibitor anticoagulant.
